Creating therapies with macrocycles could spur biologics development

02/14/2013 | Xconomy

Comparatively few biologic drugs are making it to the market, and many of those are for rare diseases, writes Nick Terrett, chief science officer at Ensemble Therapeutics. Part of the reason is the difficulty of developing biologic drugs, but the industry could use a paradigm shift in how it develops drugs, Terrett writes. Combining small-molecules and biologics could create a new therapy option, the macrocycle, he writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA